Many patients with cancer have benefited from anti-angiogenic (AA) therapies since 2004, when bevacizumab (a monoclonal-antibody against vascular endothelial growth factor (VEGF)) was approved by the U.S. FDA. This evidence concerns the gene VEGFA and cancer.